{"classes":[{"categories":[{"measurements":[{"comment":"NA indicates data was not available since geometric coefficient of variation could not be calculated for single participant.","groupId":"OG000","spread":"NA","value":"2.90"},{"comment":"NA indicates data was not available since geometric coefficient of variation could not be calculated for single participant.","groupId":"OG001","spread":"NA","value":"5.70"},{"comment":"NA indicates data was not available since geometric coefficient of variation could not be calculated for single participant.","groupId":"OG002","spread":"NA","value":"7.10"},{"comment":"NA indicates data was not available since geometric coefficient of variation could not be calculated for single participant.","groupId":"OG003","spread":"NA","value":"12.30"},{"groupId":"OG004","spread":"25","value":"26.85"},{"groupId":"OG005","spread":"14","value":"53.66"},{"groupId":"OG006","spread":"25","value":"59.70"},{"groupId":"OG007","spread":"25","value":"111.32"},{"groupId":"OG008","spread":"36","value":"157.88"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"4"}],"units":"Participants"}],"description":"Blood samples were collected from participants for pharmacokinetic analysis including AUC (0-tau) following repeat (Day 15) dose administration of GSK2816126. Pharmacokinetic analysis of GSK2816126 in Part 1 was conducted by non-compartmental methods. NA indicates data was not available since geometric coefficient of variation could not be calculated for single participant.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Eligible participants received GSK2816126 with a starting dose of 50 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG000","title":"Part 1:GSK2816126 50 mg Twice-weekly"},{"description":"Eligible participants received GSK2816126 with a dose of 100 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG001","title":"Part 1:GSK2816126 100 mg Twice-weekly"},{"description":"Eligible participants received GSK2816126 with a dose of 200 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG002","title":"Part 1:GSK2816126 200 mg Twice-weekly"},{"description":"Eligible participants received GSK2816126 with a dose of 400 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG003","title":"Part 1:GSK2816126 400 mg Twice-weekly"},{"description":"Eligible participants received GSK2816126 with a dose of 800 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG004","title":"Part 1:GSK2816126 800 mg Twice-weekly"},{"description":"Eligible participants received GSK2816126 with a dose of 1200 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG005","title":"Part 1:GSK2816126 1200 mg Twice-weekly"},{"description":"Eligible participants received GSK2816126 with a dose of 1800 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG006","title":"Part 1:GSK2816126 1800 mg Twice-weekly"},{"description":"Eligible participants received GSK2816126 with a dose of 2400 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG007","title":"Part 1:GSK2816126 2400 mg Twice-weekly"},{"description":"Eligible participants received GSK2816126 with a dose of 3000 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG008","title":"Part 1:GSK2816126 3000 mg Twice-weekly"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic Population. Only those participants with data available at specific time point were analyzed.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.5, 1, 2, 24, and 96 hours post-dose from start of infusion; 0.5, 1, 2, 4, 6 hours from end of infusion on Cycle 1 of Day 15 (Each cycle was of 28 days)","title":"Part 1: Area Under the Concentration-time Curve Over the Dosing Interval (AUC [0-tau]) Following Repeat Dose Administration of GSK2816126","type":"SECONDARY","unitOfMeasure":"Hour*Microgram per milliliter"}